The Psychiatric Pipeline in Review: Quarter 1, 2025
Additional Positive Data on LB-102 for the Treatment of Acutely Exacerbated Schizophrenia
Phase 2 Trial Open Enrollment for SPG302, First Synaptic Regenerative Approach to Treat Schizophrenia
It Was National Doctors’ Day and a Top Vaccine Expert Resigned